Amel Med LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$441,805	96
2024	Research	$98,910	16
2023	Research	$15,884	3
2022	Research	$29,914	1

Breakdown

Who paid Research payments · program years 2022–2025

AbbVie, Inc. $220,773 25 payments
Genentech, Inc. $179,790 38 payments
Takeda Pharmaceuticals U.S.A., Inc. $83,192 40 payments
Janssen Research & Development, LLC $53,508 8 payments
Eli Lilly and Company $36,298 3 payments
Bausch Health US, LLC $9,500 1 payment
F. Hoffmann-La Roche AG $3,453 1 payment

Studies the money was for Research payments · program years 2022–2025

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) $151,687 30 payments
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $87,279 14 payments
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $69,035 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of Tak-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on A Gluten-Free Diet $65,942 38 payments
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants $47,443 7 payments
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) $42,553 4 payments
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) $31,556 9 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $29,914 1 payment
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohns Disease $17,697 3 payments
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) $17,250 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.